Companies: 48,874 Total Market Cap: 132391982605079.18

Almirall, S.A.

BME-ALM
Healthcare Drug Manufacturers - Specialty & Generic
Rank #5314
Market Cap 2.40 B
Volume 115,639
Price 11.22
Change (%) 1.87%
Country or region Spain Spain

Almirall, S.A.'s latest marketcap:

2.40 B

As of 05/19/2025, Almirall, S.A.'s market capitalization has reached $2.40 B. According to our data, Almirall, S.A. is the 5314th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 2.40 B
Revenue (ttm) 1.15 B
Net Income (ttm) 27.36 M
Shares Out 213.47 M
EPS (ttm) 0.13
Forward PE 30.03
Ex-Dividend Date 05/15/2025
Earnings Date 05/12/2025
Market Cap Chart
Data Updated: 05/19/2025

Almirall, S.A.'s yearly market capitalization.

Almirall, S.A. has seen its market value grow from €1.95 B to €2.13 B since 2020, representing a total increase of 9.64% and an annual compound growth rate (CAGR) of 2.12%.
Date Market Cap Change (%)
05/19/2025 €2.13 B 31.15%
12/31/2024 €1.76 B -0.35%
12/29/2023 €1.76 B 7.51%
12/30/2022 €1.64 B -19.23%
12/30/2021 €2.03 B 4.44%
12/31/2020 €1.95 B

Company Profile

About Almirall, S.A.

Almirall, S.A. is a biopharmaceutical company specializing in skin health, operating across Spain, Europe, the Middle East, the United States, Asia, and Africa.

Product Portfolio

The company provides treatments for a wide range of skin conditions, including:

  • Psoriasis
  • Atopic dermatitis
  • Acne
  • Actinic keratosis
  • Onychomycosis
  • Androgenic alopecia
  • Oncodermatology
  • Orphan indications

Additionally, Almirall offers products for:

  • Alimentary tract and metabolism
  • Antiinfectives for systemic use
  • Cardiovascular, musculoskeletal, nervous, and respiratory systems
  • Dermatologicals
  • Genito urinary system and sex hormones
  • Immunostimulants
  • Metabolism
  • Systematic hormonal preparations

Partnerships & Research

Almirall has a multi-target partnership with Etherna to advance mRNA-based therapies for medical dermatology.

Company Background

Founded in 1943, the company was formerly known as Laboratorios Almirall, S.A. before rebranding to Almirall, S.A. in May 2009. Its headquarters are located in Barcelona, Spain.

Frequently Asked Questions

As of 05/19/2025, Almirall, S.A. (including the parent company, if applicable) has an estimated market capitalization of $2.40 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Almirall, S.A. global market capitalization ranking is approximately 5314 as of 05/19/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region Spain
Founded 1943
IPO Date n/a
Employees 2,026
CEO Carlos Gallardo Piqué
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Address Ronda General Mitre, 151
Barcelona, 08022
Spain
Website https://www.almirall.com
People Also Watch
Zoetis
163.90 1.87%
Merck KGaA
129.22 1.87%
Haleon plc
541.90 1.87%
NSE-SUNPHARMA
20.24 1.87%